• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

老年人肺炎球菌疫苗：挪威的经验

Pneumococcal vaccine in the elderly: the Norwegian experience.

作者信息

Aaberge I S

机构信息

Department of Vaccinology, National Institute of Public Health, Oslo, Norway.

出版信息

Drugs Aging. 1999;15 Suppl 1:37-41. doi: 10.2165/00002512-199915001-00005.

DOI:10.2165/00002512-199915001-00005
PMID:10690794
Abstract

Pneumococcal infections have increased during the last 10 to 15 years in Norway. Their incidence is now about 20 per 100,000 population for all age groups, but is 2 to 3 times higher among the elderly. In 1996, the Advisory Board of Infectious Disease Control, National Institute of Public Health, Norway, recommended that pneumococcal polysaccharide vaccine should be administered to all individuals aged > or = 65 years. This recommendation has led to an increased use of pneumococcal vaccine, with a marked peak during the influenza vaccination season.

摘要

在过去10到15年中，挪威的肺炎球菌感染病例有所增加。目前，所有年龄组的发病率约为每10万人20例，但老年人的发病率要高出2至3倍。1996年，挪威国家公共卫生研究所传染病控制咨询委员会建议，应为所有年龄大于或等于65岁的人接种肺炎球菌多糖疫苗。这一建议导致肺炎球菌疫苗的使用增加，在流感疫苗接种季节出现了明显的高峰。

相似文献

1
Pneumococcal vaccine in the elderly: the Norwegian experience.老年人肺炎球菌疫苗：挪威的经验
Drugs Aging. 1999;15 Suppl 1:37-41. doi: 10.2165/00002512-199915001-00005.
2
Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).肺炎球菌疾病的预防：免疫实践咨询委员会（ACIP）的建议。
MMWR Recomm Rep. 1997 Apr 4;46(RR-8):1-24.
3
Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996.1981 - 1996年美国及其他20个发达国家的肺炎球菌疫苗接种情况
Clin Infect Dis. 1998 May;26(5):1117-23. doi: 10.1086/520272.
4
Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.老年人接种肺炎球菌血症疫苗的成本效益
JAMA. 1997;278(16):1333-9.
5
Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).预防婴幼儿肺炎球菌疾病。免疫实践咨询委员会（ACIP）的建议。
MMWR Recomm Rep. 2000 Oct 6;49(RR-9):1-35.
6
Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.在英国为老年人和高危成年人接种23价肺炎球菌多糖疫苗或13价肺炎球菌结合疫苗的成本效益
Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):913-27. doi: 10.1586/14737167.2014.950232. Epub 2014 Sep 5.
7
Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.在挪威儿童疫苗接种计划中添加7价肺炎球菌结合疫苗（PCV - 7）的成本效益。
Vaccine. 2006 Jul 17;24(29-30):5690-9. doi: 10.1016/j.vaccine.2006.04.042. Epub 2006 May 5.
8
[The elderly should be vaccinated against pneumococci].老年人应该接种肺炎球菌疫苗。
Lakartidningen. 1999 Mar 17;96(11):1305-8.
9
Cost-effectiveness of pneumococcal vaccine.肺炎球菌疫苗的成本效益
JAMA. 2000 Jul 26;284(4):440; author reply 440-1.
10
Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.肺炎球菌多糖结合疫苗（与 CRM197 载体蛋白结合）在儿童和成人中的应用经验。
Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9. doi: 10.1111/1469-0691.12320.

本文引用的文献

1
Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group.23价肺炎球菌荚膜多糖疫苗预防中老年人肺炎的随机试验。瑞典肺炎球菌疫苗接种研究组
Lancet. 1998 Feb 7;351(9100):399-403. doi: 10.1016/s0140-6736(97)07358-3.
2
Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial.肺炎球菌疫苗对老年人的临床疗效：一项基于人群的随机单盲试验。
Am J Med. 1997 Oct;103(4):281-90. doi: 10.1016/s0002-9343(97)00149-6.
3
Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.
老年人接种肺炎球菌血症疫苗的成本效益
JAMA. 1997;278(16):1333-9.
4
Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).肺炎球菌疾病的预防：免疫实践咨询委员会（ACIP）的建议。
MMWR Recomm Rep. 1997 Apr 4;46(RR-8):1-24.
5
Systemic pneumococcal disease after staging splenectomy for Hodgkin's disease 1969-1980 without pneumococcal vaccine protection: a follow-up study 1994.1969 - 1980年霍奇金病分期脾切除术后无肺炎球菌疫苗保护情况下的全身性肺炎球菌疾病：1994年随访研究
Eur J Haematol. 1997 Feb;58(2):73-7. doi: 10.1111/j.1600-0609.1997.tb00927.x.
6
Incidence of invasive pneumococcal disease and distribution of capsular types of pneumococci in Denmark, 1989-94.1989 - 1994年丹麦侵袭性肺炎球菌疾病的发病率及肺炎球菌荚膜类型分布
Epidemiol Infect. 1996 Dec;117(3):411-6. doi: 10.1017/s0950268800059057.
7
Incidence, capsular types, and antibiotic susceptibility of invasive Streptococcus pneumoniae in Sweden.
Clin Infect Dis. 1995 Oct;21(4):948-53. doi: 10.1093/clinids/21.4.948.
8
Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations.肺炎球菌多糖疫苗的效力。对当前建议的评估。
JAMA. 1993 Oct 20;270(15):1826-31.
9
[All persons without spleen should be given pneumococcal vaccine].所有无脾者均应接种肺炎球菌疫苗。
Tidsskr Nor Laegeforen. 1994 Sep 30;114(23):2732-3.
10
[High incidence and mortality of systemic pneumococcal disease among persons without spleen].无脾者中系统性肺炎球菌病的高发病率和高死亡率
Tidsskr Nor Laegeforen. 1994 Sep 30;114(23):2711-4.